EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Hydrochlorothiazide Use and Risk of Skin Cancer: A Population‐Based Retrospective Cohort Study

Avery Shuei-He Yang iD, Leila Djebarri, Chaw Ning Lee, Denis Granados iD, Mohamed Abdel Moneim, Shih-Chieh Shao, Swu-Jane Lin, Tzu-Chi Liao, Hung-Wei Lin, Edward Chia-Cheng Lai iD

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70027 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Avery Shuei-He Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwa…. Hauptthemen laut MEDLINE: Skin Neoplasms, Hydrochlorothiazide, Antihypertensive Agents, Basal Cell Carcinoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Hydrochlorothiazide (HCTZ) exposure has been linked to increased skin cancer in Caucasian (white) populations, especially squamous cell carcinoma (SCC), but not basal cell carcinoma (BCC). This study aimed to evaluate and compare skin cancer risks associated with HCTZ‐ and other antihypertensives use.

Methods

This retrospective cohort study utilized Taiwan's National Health Insurance Research Database. We identified patients aged 20 years and older, newly receiving antihypertensive medications between 2004 and 2015. We calculated the medication possession ratio (MPR) for the first 2 years of treatment to determine patient eligibility and treatment classification, whereby only patients with MPR above 80% were included. These were subsequently categorized by the type of antihypertensives they received, namely HCTZ, other thiazide diuretics, non‐thiazide diuretics or non‐diuretic antihypertensives. Cox proportional hazards model was used to evaluate skin cancer risks, and these were then classified as SCC or BCC.

Results

Our study included 41 086, 27 402, 19 613, and 856 782 patients receiving HCTZ, other thiazide diuretics, non‐thiazide diuretics, and non‐diuretic antihypertensives, respectively. We found BCC risks were similar when comparing HCTZ with other thiazides (adjusted hazard ratio: 0.84; 95% CI: 0.54–1.33), non‐thiazide diuretics (0.93; 0.51–1.67), and non‐diuretic antihypertensives (0.91; 0.66–1.26). We observed a higher SCC risk in the HCTZ group, compared to other thiazides (1.24; 0.74–2.08), non‐thiazide diuretics (1.32; 0.70–2.51), and non‐diuretic antihypertensives (1.23; 0.87–1.73), although the confidence intervals (CIs) were wide and crossed the null.

Conclusions

We concluded that skin cancer need not be of major concern to physicians when prescribing antihypertensives for an Asian population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsHydrochlorothiazideAntihypertensive AgentsBasal Cell CarcinomaHumansRetrospective StudiesMaleFemaleMiddle AgedAgedAdultTaiwanCarcinoma, Squamous CellDatabases, FactualCohort StudiesSodium Chloride Symporter InhibitorsYoung AdultHypertensionRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

antihypertensive agentbasal cell carcinoma and squamous cell carcinomahydrochlorothiazidenon‐melanoma skin cancer

Substanzen

HydrochlorothiazideAntihypertensive AgentsSodium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Pharmacoepidemiology department, Sanofi, Paris, France.
  • Department of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Medical cardiovascular department, Sanofi Aventis, Dubai, UAE.
  • Department of Pharmacy, Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.

ORCID-Profile: Avery Shuei-He Yang, Denis Granados, Edward Chia-Cheng Lai

Förderung

  • Sanofi

Zitieren

APA

Yang, A. S., Djebarri, L., Lee, C. N., Granados, D., Moneim, M. A., Shao, S. C., Lin, S. J., Liao, T. C., Lin, H. W., & Lai, E. C. (2024). Hydrochlorothiazide Use and Risk of Skin Cancer: A Population‐Based Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70027

Vancouver

Yang AS, Djebarri L, Lee CN, Granados D, Moneim MA, Shao SC, et al. Hydrochlorothiazide Use and Risk of Skin Cancer: A Population‐Based Retrospective Cohort Study. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70027

BibTeX
@article{Yang2024,
  author = {Yang, Avery Shuei-He and Djebarri, Leila and Lee, Chaw Ning and Granados, Denis and Moneim, Mohamed Abdel and Shao, Shih-Chieh and Lin, Swu-Jane and Liao, Tzu-Chi and Lin, Hung-Wei and Lai, Edward Chia-Cheng},
  title = {Hydrochlorothiazide Use and Risk of Skin Cancer: A Population‐Based Retrospective Cohort Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70027}
}
Kostenlos starten →